ABL1 and acute lymphoblastic leukemia: The traditional view is that deletions of crucial genes that control proliferation, survival, and B cell differentiation are required for BCR-ABL+ B-ALL transformation, making the leukemic cells independent of BCR-ABL activity and therefore insensitive to TKI therapies.